MINNEAPOLIS, Nov. 6, 2015 /PRNewswire-USNewswire/
-- DaVita Clinical Research (DCR), a specialty contract
research organization with services spanning the full spectrum of
drug and device development, today announced the recipients of the
Biospecimen Research Grant Program, a grant
program to award clinical-trial-quality biospecimens and annotated
de-identified data to qualifying academic medical centers involved
in kidney research.
The goal of the program is for recipients to utilize
biospecimens and associated de-identified data to research common
factors or characteristics that contribute to morbidity and
mortality in individuals with chronic kidney disease. Four
recipients have been selected for grant awards, subject to the
terms of the grant program:
- Brigham and Women's Hospital: Dr. Sushrut Waikar
- Johns Hopkins University: Dr. Tariq
Shafi
- University of California-Irvine:
Dr. Kamyar Kalantar-Zadeh
- University of
Tennessee-Memphis: Dr. Csaba P. Kovesdy
Qualifying applications were selected based on the following
established criteria: scientific and medical significance,
investigator qualifications, innovation, approach and design,
research environment and institutional support.
"DCR is committed to advancing the evidence-based practice of
medicine in chronic kidney disease," said Steven M. Brunelli, M.D., vice president of
health outcomes research for DCR. "We recognize the significant
contributions made by academic medical organizations toward that
end and we look forward to seeing the results of these research
projects as we continue to work with other organizations to improve
the collective knowledge of chronic kidney disease."
DCR created the biorepository using IRB approved protocol and
consent with rigorous clinical trial procedures for the collection
and storage of samples. This resulted in whole blood, plasma and
serum samples collected longitudinally from more than 4,000
individuals receiving dialysis. These samples are linked with
de-identified data sets, including demographics, co-morbidities,
hospitalizations, lab values, medication data and cause of death
(if available/applicable).
DaVita Clinical Research and DCR are registered trademarks of
DaVita HealthCare Partners Inc.
About DaVita Clinical Research (DCR)
DaVita Clinical
Research (DCR), a wholly owned subsidiary of DaVita HealthCare
Partners Inc. (NYSE: DVA), uses its extensive, applied database and
real-world health care experience to assist pharmaceutical and
medical device companies in the design, recruitment and completion
of retrospective, prospective and pragmatic clinical trials. DCR's
scientific and clinical expertise spans the lifecycle of product
development with more than 175 client companies. DCR's early
clinical research unit (Phase I-IIa) and late phase clinical
research (Phase IIb through post-marketing) network of physicians
and investigative sites, real-world health care data, health
economics and outcomes research, and medical communications are
focused on providing world-class research in both complex/specialty
populations and therapeutic areas, and especially in CKD and ESRD
populations. To learn more about DCR, visit
www.davitaclinicalresearch.com.
Media Contact:
Bianca
Violante
Office: (303) 876-6614
Mobile: (443) 417-6044
Bianca.Violante@DaVita.com
Logo -
http://photos.prnewswire.com/prnh/20140212/DC63568LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/recipients-of-bio-specimen-grant-program-bioreg-announced-during-kidney-week-300173827.html
SOURCE DaVita Clinical Research